Literature DB >> 11129758

Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy.

M M Verrico1, D A Nace, A L Towers.   

Abstract

OBJECTIVE: To describe a case of fulminant hepatitis possibly related to concomitant donepezil and seratriline therapy. PATIENT AND
SETTING: An 83-year-old woman treated in a dementia care facility and later in a tertiary medical center. INTERVENTION AND MANAGEMENT: Discontinuation of donepezil and sertraline therapy with subsequent improvement evidenced by liver biopsy and liver function tests.
RESULTS: An older woman with Alzheimer's disease was admitted to a dementia care facility because of aggressive behavior. Treatment with sertraline was initiated in February 1998. Sertraline doses were increased gradually to 200 mg daily by May 1998, and some improvement in behavior was seen. Concomitant therapy with donepezil 5 mg qhs was initiated June 26, 1998. Ten days later, confusion and jaundice were noted. Total bilirubin was 5.6 mg/dL, GGTP was 1,208 IU/L, and alkaline phosphatase was 369 IU/L. Computed tomography revealed cholelithiasis without ductal dilation. Liver, spleen, and pancreas seemed normal. Donepezil and sertraline were discontinued. The patient was admitted to our institution and treated for dehydration. A liver biopsy revealed scattered portal eosinophils and prominent cholestasis consistent with acute chemical hepatitis. The GGTP and total bilirubin of this patient peaked at 2,235 IU/L and 22.6 mg/dL, respectively. The patient improved, and her liver function tests normalized over the next 2 months.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129758     DOI: 10.1111/j.1532-5415.2000.tb03879.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  14 in total

1.  Sertraline hepatotoxicity: report of a case and review of the literature.

Authors:  Virginia Collados; Hacibe Hallal; Raúl J Andrade
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Mitochondrial dysfunction induced by sertraline, an antidepressant agent.

Authors:  Yan Li; Letha Couch; Masahiro Higuchi; Jia-Long Fang; Lei Guo
Journal:  Toxicol Sci       Date:  2012-03-02       Impact factor: 4.849

3.  Sertraline induces endoplasmic reticulum stress in hepatic cells.

Authors:  Si Chen; Jiekun Xuan; Letha Couch; Advait Iyer; Yuanfeng Wu; Quan-Zhen Li; Lei Guo
Journal:  Toxicology       Date:  2014-05-24       Impact factor: 4.221

4.  Acute liver injury secondary to sertraline.

Authors:  Christopher F D Li Wai Suen; Ray Boyapati; Ian Simpson; Anouk Dev
Journal:  BMJ Case Rep       Date:  2013-09-26

Review 5.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Sertraline hepatotoxicity: report of a case and review of the literature.

Authors:  Fehmi Tabak; Feyza Gunduz; Veysel Tahan; Omur Tabak; Resat Ozaras
Journal:  Dig Dis Sci       Date:  2008-10-29       Impact factor: 3.199

Review 7.  Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity.

Authors:  Seth Persky; John F Reinus
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 8.  Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity.

Authors:  Si Chen; William B Melchior; Lei Guo
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2014       Impact factor: 3.781

Review 9.  Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.

Authors:  Danièle Bentué-Ferrer; Olivier Tribut; Elisabeth Polard; Hervé Allain
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  The role of hepatic cytochrome P450s in the cytotoxicity of sertraline.

Authors:  Si Chen; Qiangen Wu; Xilin Li; Dongying Li; Michelle Fan; Zhen Ren; Matthew Bryant; Nan Mei; Baitang Ning; Lei Guo
Journal:  Arch Toxicol       Date:  2020-05-05       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.